1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MediWound Ltd.
  6. News
  7. Summary
    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MediWound Says Phase 2 Study of EscharEx Treatment for Chronic Wounds Delivers Positive Preliminary Data

12/20/2021 | 10:05am EDT


© MT Newswires 2021
All news about MEDIWOUND LTD.
05/18Wells Fargo Adjusts MediWound's Price Target to $8 From $7, Keeps Overweight Rating
MT
05/17SECTOR UPDATE : Health Care Stocks Rising Ahead of Tuesday Close
MT
05/17SECTOR UPDATE : Health Care Stocks Firming with Broader Market Gains
MT
05/17TRANSCRIPT : MediWound Ltd., Q1 2022 Earnings Call, May 17, 2022
CI
05/17MediWound Appoints Ofer Gonen as CEO
MT
05/17MEDIWOUND : Q1 Earnings Snapshot
AQ
05/17MediWound Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/17MediWound Announces CEO Transition
GL
05/17MediWound Announces CEO Transition
GL
05/17MediWound Reports First Quarter 2022 Financial Results
GL
More news
Analyst Recommendations on MEDIWOUND LTD.
More recommendations
Financials (USD)
Sales 2022 21,4 M - -
Net income 2022 -11,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,87x
Yield 2022 -
Capitalization 58,8 M 58,8 M -
Capi. / Sales 2022 2,74x
Capi. / Sales 2023 2,10x
Nbr of Employees -
Free-Float 59,6%
Chart MEDIWOUND LTD.
Duration : Period :
MediWound Ltd. Technical Analysis Chart | MDWD | IL0011316309 | MarketScreener
Technical analysis trends MEDIWOUND LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,81 $
Average target price 6,25 $
Spread / Average Target 245%
EPS Revisions
Managers and Directors
Sharon Malka Chief Executive Officer
Boaz Gur-Lavie Chief Financial Officer
Stephen T. Wills Executive Chairman
Lior Rosenberg Chief Medical Officer
Ety Klinger Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDIWOUND LTD.-23.31%59
CSL LIMITED-6.06%91 946
SAMSUNG BIOLOGICS CO.,LTD.-12.18%44 385
BIOGEN INC.-18.43%28 662
WUXI BIOLOGICS (CAYMAN) INC.-42.79%28 457
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.03%22 129